ADTX News and Press, ADiTx Therapeutics Inc. From 12/13/21

Aditxt (NASDAQ:ADTX) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 through a range of non-invasive and affordable point of care and at-home/in-office test kits. The target holds an exclusive license in ...

The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test EUA application for the COVID-19 rapid antigen test was submitted in September 2021 Target acquisition has a range of rapid Point-of-Care diagnostics within their por...

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 16,575,000 units, consist...

Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into an amendment to its previously announced transaction agreement with A...

Gainers: Arbutus Biopharma (NASDAQ:ABUS) +87%. MDJM (NASDAQ:MDJH) +41%. Context Therapeutics (NASDAQ:CNTX) +35%. Build-A-Bear Workshop (NYSE:BBW) +33%. Ardelyx (NASDAQ:ARDX) +28%. Ambarella (NASDAQ:AMBA) +25%. Roivant Sciences (NASDAQ:ROIV) +22%. Stran & Company (NASDAQ:STRN) +20%. Marpai...

Gainers: Arbutus Biopharma (NASDAQ:ABUS) +47%. Ardelyx (NASDAQ:ARDX) +31%. Context Therapeutics (NASDAQ:CNTX) +19%. ImmunoGen (NASDAQ:IMGN) +17%. Skylight Health Group (NASDAQ:SLHG) +16%. Losers: BeyondSpring (NASDAQ:BYSI) -53%. Aditxt (NASDAQ:ADTX) -25%. CTI (NASDAQ:CTIC)...

Aditxt (ADTX -25.6%) prices an underwritten public offering of ~16.58M units for $1.05 per unit; gross proceeds of ~$17.4M. Underwriter's granted a 45-day option to purchase up to ~2.49M additional shares of common stock and/or warrants. Offering is expected to close on December 3, ...

Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 16,575,000 units, consisting of shares of its c...

Aditxt (NASDAQ:ADTX) announces the launch of of the common stock and warrants in a public offering. Price, size and other terms are not yet determined. Dawson James Securities is acting as sole book-running manager for the offering. Shares down 19.8% after-hours. Yesterday's cl...

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the launch of an underwritten public offering. Dawson James Securities, Inc. is acting as sole book-running manager for the o...